跳至主要内容
临床试验/NCT05004077
NCT05004077终止4 期

Repeated Amiodarone Dosing In Cardiac surgicaL Procedures

Kevin W Hatton, MD, PhD1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2021年11月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
发起方
入组人数
3
试验地点
1
主要终点
Normal Sinus Rhythm -24 HRS

研究概览

简要总结

This study is a single-center, prospective, randomized, open-label trial of subjects who develop atrial fibrillation after non-emergent cardiac surgery at the University of Kentucky Chandler Medical Center (UKCMC). Patients will be randomized to receive either a conventional amiodarone dosing regimen (CDR) or a repeated amiodarone bolus dosing regimen (RBDR).

详细描述

This study will screen and consent approximately 150 patients undergoing non-emergent cardiac surgery. Approximately 60 of these patients are likely to develop stable postoperative atrial fibrillation (POAF) in the postoperative period. Amiodarone is commonly given as an initial intravenous (IV) bolus (150 mg IV) followed by a combined IV and oral load to a total dose of 8 gm. Because of amiodarone's beta-blocker activity, the IV bolus in patients with POAF is associated with a reduced heart rate that may lead to restoration of NSR. For this reason, some clinicians will provide up to 5 additional IV amiodarone boluses during the drug's loading period to treat RVR.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject must be 18 years old or older
  • Subject must be willing to give written informed consent
  • Subject must undergo or scheduled for non-emergent cardiac surgery, including coronary artery bypass grafting (CABG), non-infectious valve repair or replacement, atrial or septal defect repair, thoracic aortic replacement surgery, or any combination of these procedures

排除标准

  • Documented allergy to amiodarone or iodine
  • History of atrial fibrillation or other heart conduction system abnormality
  • History of cardiac maze, pulmonary vein isolation, or other procedure affecting the conduction system
  • Scheduled cardiac maze, pulmonary vein isolation, or other procedure affecting the conduction system
  • Low cardiac index or cardiogenic shock requiring pharmacologic or mechanical support
  • History of pre-existing respiratory system disease requiring oxygen therapy prior to admission
  • History of cirrhosis or other chronic liver diseases
  • Pregnancy or breastfeeding mothers
  • Prisoner status

研究组 & 干预措施

Conventional amiodarone dosing regimen (CDR)

Active Comparator

Initial amiodarone bolus of 150 mg IV over 10 minutes then a 24-hour amiodarone loading infusion (1 mg/min for 6 hours followed by 0.5 mg/min for 18 hours), followed by enteral (400 mg amiodarone oral or per tube three times daily or 2 times daily if the patient has gastrointestinal intolerance when taking the drug three times daily) or intravenous amiodarone (0.5 mg/min continuous infusion) to complete an 8-gm total amiodarone load. Maintenance amiodarone (200 mg amiodarone oral or per tube once daily) at discretion of attending physician.

干预措施: AMIODARONE (Drug)

Repeated amiodarone bolus dosing regimen (RBDR)

Active Comparator

Initial amiodarone bolus of 150 mg IV over 10 minutes, then 1.0 mg/min IV amiodarone infusion for 6 hours, then a 0.5 mg/min IV amiodarone infusion for 18 hours, followed by enteral (400 mg amiodarone oral or per tube three times daily or 2 times daily if the patient has gastrointestinal intolerance when taking the drug three times daily) or intravenous amiodarone (0.5 mg/min continuous infusion) to complete an 8-gm total amiodarone load. In addition, patients in the RBDR will receive an additional 150 mg IV amiodarone bolus whenever the patient develops tachycardia (Heart Rate (HR) = 110 beats per minute) lasting more than 10 minutes. This bolus may be repeated up to a total of 5 times (6 total boluses) over the first 24 hours. Maintenance amiodarone (200 mg amiodarone oral or per tube once daily) at discretion of attending physician.

干预措施: AMIODARONE (Drug)

结局指标

主要结局

Normal Sinus Rhythm -24 HRS

时间窗: 24-hours after receiving amiodarone bolus

Percentage of patients who develop stable POAF after non-emergent cardiac surgery, the percentage of patients who have converted to NSR at 24-hours after receiving a repeated amiodarone bolus and loading dose regimen to the percentage of patients who have converted to NSR after a conventional amiodarone IV loading dose regimen.

次要结局

  • Total Target Heart Rate Time(24-hours after receiving amiodarone bolus)
  • Time to Target Heart Rate(24-hours after receiving amiodarone bolus)
  • Recurrent AF(duration of ICU and hospital visit, up to 20 days)
  • Normal Sinus Rhythm -Hospital Index(duration of ICU and hospital visit, up to 20 days)

研究者

发起方
Kevin W Hatton, MD, PhD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Kevin W Hatton, MD, PhD

Professor, Dept of Anesthesiology

University of Kentucky

研究点 (1)

Loading locations...

相似试验

Repeated Amiodarone Dosing In Cardiac surgicaL... | 临床试验